BPMX Craters, KPTI Surges On Deal With Anivive, PFE Seeks New Use For Old Drug

(RTTNews) - AMAG Pharmaceuticals Inc. (AMAG) has announced a proposed offering of $250 million of convertible senior Notes due 2022.

The Company expects to grant the underwriters an option to purchase, exercisable within a 30-day period, up to an additional $37.5 million principal amount of notes, solely to cover over-allotments, if any.

AMAG closed Wednesday's trading at $20.50, down 4.43%.

Shares of Aratana Therapeutics Inc. (PETX) were down 4% in extended trading on Wednesday after the Company priced its registered direct offering.

The Company has entered into a securities purchase agreement with several institutional investors providing for the issuance and sale of an aggregate of 5 million shares of its common stock at a price of $5.25 per share in a registered direct offering.

PETX closed Wednesday's trading at $6.22, down 2.05%.

Shares of Biopharmx Corp. (BPMX) were down 29% in after-hours on Wednesday, despite its phase 2b clinical trial of BPX-011 for the treatment of moderate-to-severe acne meeting the primary endpoint.

The trial met the primary endpoint of statistically significant reductions in non-nodular inflammatory acne lesions with BPX-011 compared to vehicle. However, the secondary endpoint of Investigator's Global Assessment (IGA), which is defined as the proportion of subjects with at least a two-grade reduction in IGA to clear "0" or almost clear "1" was not statistically significant.

The Company noted that the trial was not powered for statistical significance for IGA but was included to inform the design of the pivotal phase 3 program.

Based on the phase 2b results, BioPharmX continues to progress BPX-01 towards phase III testing.

BPMX closed Wednesday's trading at $0.85, up 1.19%. In after-hours, the stock fell 29.41% to $0.60.

Shares of Karyopharm Therapeutics Inc. (KPTI) rose more than 29% in extended trading on Wednesday, following a global license agreement with privately-held Anivive Lifesciences.

Under the agreement, Anivive has licensed from Karyopharm exclusive worldwide rights to research, develop and commercialize Verdinexor (KPT-335) for the treatment of cancer in companion animals.

The agreement entitles Karyopharm to receive $1 million upfront payment, up to $43.5 million in future milestones, and up to low double-digit royalty payments based on future net sales of Verdinexor.

KPTI closed Wednesday's trading at $9.49, down 2.47%. In after-hours, the stock soared 29.61% to $12.30.

Nymox Pharmaceutical Corp. (NYMX) has filed to seek marketing approval for Fexapotide Triflutate in Europe.

Fexapotide Triflutate, for the indication of treatment of the symptoms of benign prostatic hyperplasia, has been in development by Nymox for 15 years. This is the first filing for Fexapotide Triflutate.

Nymox will hold a teleconference call for shareholders next week.

NYMX closed Wednesday's trading at $4.10, up 16.48%.

Pfizer Inc.'s (PFE) supplemental New Drug Application for XELJANZ 5 mg twice daily for the treatment of adult patients with active psoriatic arthritis and a supplemental New Drug Application for extended release 11 mg once daily use for the treatment of adult patients with active psoriatic arthritis have been accepted for review by the FDA.

A decision on the supplemental New Drug Applications for XELJANZ is expected in December 2017.

XELJANZ is already approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

First-quarter 2017 sales of Xeljanz were $250 million compared to $197 million reported in the year-ago quarter.

PFE closed Wednesday's trading at $33.47, down 0.42%.

Theratechnologies Inc.'s (TH.TO) partner, TaiMed Biologics, Inc., has completed the submission of a Biologics License Application to the FDA for Ibalizumab for the treatment of multidrug resistant Human Immunodeficiency Virus-1.

If approved, Ibalizumab will be the first antiretroviral treatment (ART) with a new mechanism of action to be introduced in nearly 10 years and the only treatment that does not require daily dosing.

TH.TO closed Wednesday's trading at C$6.50, down 0.61%.

Shares of Windtree Therapeutics Inc. (WINT) plunged 27% in extended trading on Wednesday, following the Notice of Delisting from NASDAQ.

Since the Company no longer satisfies the listing requirement of maintaining a minimum of $2.5 million in stockholders' equity, the Company's shares will be delisted from the NASDAQ Capital Market, and trading in its shares will be suspended at the open of business on Friday, May 5, 2017.

WINT closed Wednesday's trading at $1.11, up 6.73%. In after-hours, the stock was down 27.03% to $0.81.